Olaparib Demonstrates Survival Benefit in Early Breast Cancer: Data from the phase 3 OlympiA trial (NCT02032823) showed that ...

More than 100 000 women older than 70 years are diagnosed with hormone receptor-positive, early-stage breast cancer each year in the USA.1 A large proportion are at low risk of disease recurrence, ...

Neoadjuvant chemotherapy's effect on local disease management of breast cancer has a number of clinical implications, including tumor downsizing, potentially improved overall survival, and more.

Neoadjuvant therapy for high-risk renal cell carcinoma (RCC) may offer a survival advantage over adjuvant therapy, according to data presented at the 2024 annual meeting of the Society of Urologic ...

Research presented at SABCS 2024 highlighted efforts to expand treatment options for early breast cancer as well as ...

The most-read breast cancer articles include topics on hereditary breast cancer, hormone therapy benefits, BRCA mutations, as ...

For patients with "good-risk" ductal carcinoma in situ (DCIS) who underwent breast-conserving surgery and did not receive ...